FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
States Sue Trump Administration Over SNAP Restrictions for Legal Immigrants 
Key Witness Seeks to Block Evidence in Potential Revival of Comey Case 
Visa to Move European Headquarters to London’s Canary Wharf 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Trump Vows Pardon for Former Honduran President as Honduras Faces Tight Election 
Singapore Court Allows $2.7 Billion 1MDB Lawsuit Against Standard Chartered to Proceed 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Netanyahu Seeks Presidential Pardon Amid Ongoing Corruption Trial 
Judge Dismisses Charges Against Comey and Letitia James After Ruling on Prosecutor’s Appointment 
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict 
Chemours, Dupont De Nemours, and Corteva have announced a $110 million settlement with the U.S. state of Ohio to resolve claims linked to toxic "forever chemicals." This agreement aims to address concerns surrounding per- and polyfluoroalkyl substances (PFAS).
Nasdaq reported that the chemical has been associated with various health risks. The settlement covers costs related to the release of PFAS from the companies' facilities, including the Washington Works site situated along the Ohio-West Virginia border, as per Reuters.
Responsibility Distribution for Settlement Costs
According to the agreement, Chemours, a spin-off of DuPont, will bear 50% of the settlement costs, while DuPont will contribute approximately $39 million. Corteva, on the other hand, is expected to cover the remaining expenses. The resolution brings an end to Ohio's claims concerning the release of PFAS, affording the state an opportunity to address this issue comprehensively.
The resolution of the Ohio settlement emphasizes the importance of addressing the wide-reaching implications of PFAS contamination.
Notably, the settlement between the companies and Ohio has triggered a contingency provision outlined in Delaware's 2021 PFAS settlement with the same entities.
This provision requires an additional payment of $25 million to the state of Delaware and the original $50 million settlement if a similar agreement is reached within eight years with another state, amounting to over $50 million. This provision underlines the accountability held by chemical manufacturers in addressing the concerns associated with PFAS contamination.
Legal Battles Surrounding PFAS
Chemical manufacturers have faced numerous lawsuits in recent years regarding alleged PFAS contamination. In a significant ruling, a U.S. appeals court rejected a lower court's decision that would have allowed approximately 11.8 million Ohio residents to sue 10 PFAS manufacturers as a collective group. The legal landscape demonstrates the complexity surrounding PFAS-related claims and the efforts to hold responsible parties accountable for their actions.
In June, 3M agreed to a $10.3 billion settlement to address hundreds of claims alleging the company had contaminated public drinking water with PFAS. Similarly, Chemours, DuPont, and Corteva reached a separate settlement with U.S. water providers, amounting to $1.19 billion.
These settlements underscore the growing recognition within the industry regarding the need to address PFAS-related concerns and the responsibility manufacturers bear in ensuring the safety of their products and practices.
Photo: DuPont Newsroom
